---
title: "PDS Biotech Reports Strong Interim Data With PDS01ADC In Colorectal Cancer, Stock Up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282925796.md"
description: "PDS Biotechnology Corporation (PDSB) reported positive interim Phase 2 results for its immunocytokine PDS01ADC in metastatic colorectal cancer (mCRC). Key findings from a nine-patient cohort included a 77.8% objective response rate at six months and an 85% two-year survival rate. The therapy combines PDS01ADC with floxuridine, delivered via an FDA-approved hepatic artery infusion pump. Following the announcement, PDSB's stock rose 28.30% to $1.36, and further increased to $1.41 in overnight trading."
datetime: "2026-04-16T02:20:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282925796.md)
  - [en](https://longbridge.com/en/news/282925796.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282925796.md)
---

# PDS Biotech Reports Strong Interim Data With PDS01ADC In Colorectal Cancer, Stock Up

(RTTNews) - PDS Biotechnology Corporation (PDSB) announced positive interim Phase 2 results from Stage 1 of an NCI-led trial evaluating its tumor-targeted IL-12 immunocytokine, PDS01ADC, in patients with metastatic colorectal cancer (mCRC).

The study focused on patients with microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases- a group that makes up the majority of mCRC cases and has historically shown poor response to immune checkpoint inhibitors.

Key findings from the nine-patient cohort included:

\-Objective response rate (ORR): 77.8% at six months, compared with 35% in a parallel trial without PDS01ADC.

\-Two-year survival rate: Approximately 85%, versus approximately 40% in parallel trial.

\-Progression-free survival: Median not reached at 13.1 months follow-up, compared with 8.1 months in the parallel trial.

The trial combined subcutaneous PDS01ADC with floxuridine (FUDR), delivered via hepatic artery infusion pump (HAIP). HAIP was FDA-approved in 2024 and is gaining use at leading oncology centers.

"These early results showing strong tumor response rates a promising patient survival is encouraging and support our approach of subcutaneously administering PDS01ADC to activate the immune system against the cancer," said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. He emphasized that the targeted design of PDS01ADC aims to concentrate IL-12 at tumor sites, improving tolerability while enhancing anti-tumor potency.

PDS01ADC has been shown to promote stem-like T cells, activate natural killer cells, and inhibit immune-suppressive cells that protect tumors. The therapy is also being evaluated in other Phase 2 trials across multiple cancer indications.

Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S., with more than 150,000 new cases annually. Globally, it accounts for nearly 2 million deaths each year.

PDSB has traded between $0.50 and $1.91 over the past year. The stock closed yesterday's trading at $1.36, up 28.30%. During the overnight session the stock is at $1.41, up 3.68%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [PDSB.US](https://longbridge.com/en/quote/PDSB.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)
- [Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit | WHWK Stock News](https://longbridge.com/en/news/287060019.md)
- [Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade | PPCB Stock News](https://longbridge.com/en/news/287069272.md)
- [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md)
- [AIA Singapore targets 90% of illness claims](https://longbridge.com/en/news/287132135.md)